Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Selank vs Zilucoplan (Zilbrysq)
An educational, source-based comparison of Selank and Zilucoplan (Zilbrysq) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of the immunomodulatory peptide tuftsin. Research suggests it modulates GABAergic and serotonergic systems and influences expression of brain-derived neurotrophic factor without the sedation or dependence profile of benzodiazepines.
- Generalized anxiety models
- BDNF expression
- Immune modulation
- Memory and learning in rodent models
- • Not FDA-approved.
- • Most studies are Russian clinical literature.
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- • FDA-approved 2023.
- • Requires meningococcal vaccination — risk of serious meningococcal infection.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Selank | Selank in generalized anxiety disorder | Zhurnal Nevrologii i Psikhiatrii | 2008 | Comparable anxiolytic effect to medazepam without sedation or withdrawal. |
| Zilucoplan (Zilbrysq) | RAISE phase 3 trial of zilucoplan in gMG | Lancet Neurology | 2023 | Significant improvement in MG-ADL and QMG scores vs placebo at week 12. |
Side-effect & safety grid
- Not FDA-approved.
- Most studies are Russian clinical literature.
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Selank vs Zilucoplan (Zilbrysq) — Key differences
- Class: Selank is classified as Anxiolytic · Nootropic, while Zilucoplan (Zilbrysq) is Complement Inhibitor · Neuromuscular.
- Primary research focus: Selank — generalized anxiety models; Zilucoplan (Zilbrysq) — generalized myasthenia gravis (anti-achr antibody positive).
- Tag: Calm · Cognition vs FDA-Approved · Neuromuscular.